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enhancing the regeneration and repair 
of damaged tissues in these patients.
Generation and differentiation  
of iPS cells
The development and use of iPS cells 
comprise a rapidly evolving field that 
emerged in 2006 with the demonstration 
that somatic cells, such as skin fibroblasts 
(Takahashi and Yamanaka, 2006), epider-
mal keratinocytes (Aasen et al., 2008), and 
hair follicle outer root sheath cells (Aasen 
and Belmonte, 2010) from adults can be 
reprogrammed to an embryonic stem (ES) 
cell-like state by addition of a few select-
ed transcription factors (c-MYC, SOX2, 
OCT4, and KLF4) (Figure 1). Culturing 
and characterization of such cells then 
allow isolation of pluripotent cells with 
features of ES cells and the potential to 
differentiate into any cell type in the body.
Several characteristics indicate 
the successful generation of iPS cells 
(Table 1), including a morphology 
similar to that of human ES cells (i.e., 
small size, prominent nuclei with a 
large nucleus-to-cytoplasm ratio, and 
tight and flat colonies with clear-cut, 
round edges) and a normal karyotype. 
Expression of several stem cell markers 
must be demonstrated by immunostain-
ing or by reverse transcription–PCR—
particularly expression of the NANOG 
gene, which is not used for induction of 
iPS cells. These reprogramming factors 
At the 2010 Annual Meeting of the 
Society for Investigative Dermatology 
in Atlanta, Georgia, among the hot top-
ics were several abstracts reporting that 
induced pluripotent stem (iPS) cells can 
be differentiated into keratinocytes, sug-
gesting that such cells can be applied 
to regenerative medicine in dermatol-
ogy. Now, several months later, the 
full papers on these presentations are 
appearing in the literature. In this issue, 
two articles (Bilousova et al., 2011; Tolar 
et al., 2011) report on differentiation of 
mouse and human iPS cells into kerati-
nocytes. A complementary study (Itoh 
and Christiano, 2010) is being prepared 
for publication (Itoh et al., personal 
communication). The translational focus 
of these papers centers on epiderm-
olysis bullosa (EB), a group of heritable 
blistering diseases in which, as a result 
of mutations in as many as 14 different 
genes expressed in the epidermis and 
the cutaneous basement membrane 
zone, the skin and mucous membranes 
are extremely fragile, leading to blis-
tering and erosions with considerable 
morbidity and mortality. No effective 
or specific treatment is currently avail-
able for EB, but significant progress has 
been made recently toward the develop-
ment of DNA-, protein-, and cell-based 
therapies (Uitto et al., 2010). Generation 
of functional skin from iPS cells may 
now provide an innovative approach to 
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are thought to activate a network of tran-
scriptional factors that in turn induce 
epigenetic changes, including demethy-
lation of OCT4 and NANOG promoter 
sequences. The pluripotent capacity of 
these cells is then demonstrated by tera-
toma formation in vivo upon injection 
of iPS cells into immunocompromised 
mice, and confirming the contribution of 
iPS cells to cell lineages of endo dermal, 
mesodermal, and ectodermal origin 
using germ layer–specific markers. 
Once newly generated iPS cells have 
been characterized and their pluri potent 
capacity has been verified, they can 
theoretically be differentiated into any 
one of several lineages in vitro using cul-
ture conditions that are directed toward 
each lineage. This general scheme has 
been shown to be successful in generat-
ing special ized, well-differentiated cells, 
such as cardiomyocytes, neural cells, 
osteoblasts, blood progenitor cells, and 
insulin-producing cells. The three papers 
cited above are the first to demonstrate 
differentiation of iPS cells to keratinocytes, 
albeit using different, complementary 
methods and approaches.
From iPS cells to skin
The study by Bilousova et al. (2011) 
demonstrates directed differentiation of 
mouse iPS cells in culture into a multi-
potent keratinocyte lineage capable of 
forming a fully differentiated epidermis, 
hair follicles, and sebaceous glands in a 
reconstitutive in vivo environment. The 
key in differentiating iPS cells toward 
the ectodermal lineage is the sequen-
tial application of retinoic acid (RA) and 
bone morphogenic protein 4 (BMP4), 
which resulted in keratin 14–positive 
epidermal stem cells. This stem cell 
population could be enriched by 
selective attachment to type IV collagen-
coated surfaces, onto which the fully 
differen tiated progeny does not attach.
|Induced pluripotent cells can differentiate into keratinocytes for 
the regeneration of skin.
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The study by Itoh et al. (personal 
communication) also reports success-
ful generation of iPS cells, not only 
from normal human fibroblasts but also 
from fibroblasts isolated from the skin 
of patients with recessive dystrophic EB 
(RDEB). These investigators employed 
similar culture conditions using RA 
and BMP4, which allowed expedient 
differentiation of these iPS cells into kera-
tinocytes. Importantly, these cells were 
used to generate three-dimensional skin 
equivalents, suggesting that they were 
fully functional.
It is noteworthy that both of these 
studies drew on a foundation of knowl-
edge in ES cell biology that has emerged 
in recent years. For example, both studies 
borrowed a page from earlier work 
attesting to the utility of RA and BMP4 in 
differentiating ES cells into keratinocytes 
and subsequent reprogramming of kera-
tinocytes into a neural fate (Aberdam, 
2004; Grinnell and Bickenbach, 2007). 
In addition, the succession of markers 
that are activated as ES cells differentiate 
into keratinocytes provides a road map 
for monitoring the efficacy of directed 
differentiation of iPS cells into keratino-
cytes (Green et al., 2003).
The study by Tolar et al. (2011) takes 
a different approach. Instead of directed 
differentiation into keratinocytes in cul-
ture followed by skin-reconstitution 
assessment, these investigators used 
direct injection and teratoma formation 
to allow spontaneous differentiation of 
iPS cells into skin-like structures express-
ing keratinocyte markers. As a starting 
point, they used human fibroblasts or 
keratinocytes from normal individuals 
as well as from patients with RDEB, and 
they performed gene correction of the 
latter cells with a vector expressing type 
VII collagen. The differentiation of RDEB 
cells into corresponding iPS cells was 
similar to that observed for wild-type iPS 
cells, including the ability to differentiate 
spontaneously into structures resembling 
skin. Interestingly, these investigators also 
observed differentiation of these cells into 
hematopoietic lineages, which suggests 
that such cells could be used to generate 
autologous hematopoietic cells for graft-
ing. Collectively, these studies suggest 
that iPS cells can be differentiated into 
keratinocytes and skin-like structures, 
with the potential of treating EB.
revertant mosaicism: a unique 
opportunity for cell-based therapy
An intriguing possibility related to the 
use of iPS cells for regenerative medicine 
in dermatology centers on the potential 
of combining iPS cell technology with 
revertant mosaicism, which clinically 
manifests as patches of normal skin in 
patients with heritable skin diseases such 
as EB (Almaani et al., 2010; Pasmooij et 
al., 2010). These areas of skin reflect the 
presence of a second mutation in the 
clonal population of cells—as a result of 
back mutations, intragenic crossovers, 
or gene conversion—that negates the 
deleterious effects of the primary muta-
tion and reverses the phenotype; this 
phenomenon has been dubbed “natu-
ral gene therapy” (Lai-Cheong et al., 
2011). Thus, generation of iPS cells from 
spontaneously revertant skin would 
provide an essentially unlimited number 
of patient-specific cells for grafting in dis-
eases such as RDEB. Collectively, these 
studies attest to the potential of iPS cells 
for patient-specific stem cell therapy for 
skin diseases.
iPS cells: prospects and promises
The advantages of utilizing iPS cells for 
regenerative medicine over the ES cells 
are several. For example, the use of iPS 
cells obviates the ethical/political issues 
that have surrounded ES cells, especial-
ly in the United States. iPS cells can be 
autologous and patient specific, elimi-
nating the issues relating to immune-
based rejection of the grafts. Also, the 
generation of iPS cells can theoretically 
be scaled up, essentially providing an 
unlimited source of cells for medical 
application. So, when will iPS cell ther-
apy be available for patients? Stem cell 
researchers agree that utility of iPS cells 
for medical applications will be a reality 
eventually but that their use is only in the 
early days of development (Vogel, 2010). 
Among the several areas of uncertainty is 
the possibility that the transgenes encod-
ing reprogramming factors, which are 
ordinarily inserted into target cells via 
retro viral vectors, may cause carcino-
genesis and that inactivation of the 
viral genes will be incomplete, possibly 
leading to tumor formation. Okita et al. 
(2008), seeking to circumvent the use of 
viral genes for transfection, found that 
introduction of the corresponding tran-
scription factors in the form of proteins 
delivered to the cells allows induction of 
iPS cells without viral vectors.
Even more intriguing is the 
recent demonstration that a simple, 
noninte grating strategy of administering 
synthetic mRNAs for the transcription 
factors can result in rapid and efficient 
reprogramming of cells to pluripotency 
table 1. criteria for successful generation of induced pluripotent stem cells
Characteristic morphology and normal karyotype
Immunostaining and increased gene expression of stem cell markers (OCT4, SOX2, NANOG)
Silencing of the viral transgenes
Demethylation of stem cell gene promoters (NANOG)
Teratoma formation in vivo and contribution to all three germ layers
Somatic cell
(fibroblast)
iPS cell
Reprogramming with
transcription factors
(c-MYC, SOX2,
OCT4, KLF4)
Differentiation to
keratinocytes
(RA, BMP4)
Assembly of
epidermis
Dermis
BMZ
Epidermis
Figure 1. Schematic steps of reprogramming somatic cells, such as fibroblasts, to induced pluripotent 
stem (iPS) cells and their differentiation into epidermal keratinocytes capable of forming skin-like 
structures. The reprogramming process is initiated by the introduction of transcription factors 
(c-MYC, SOX2, OCT4, and KLF4) into the somatic cells by transduction of expression vectors, 
synthetic mRNA, or recombinant protein. The iPS cells have characteristic features that allow 
their identification and enrichment (see Table 1). The iPS cells can then be differentiated into 
keratinocytes under specific culture conditions, e.g., medium supplemented with retinoic acid (RA) 
and bone morphogenic protein-4 (BMP-4). BMZ, basement membrane zone.
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(Warren et al., 2010). Because the exog-
enously administered RNA molecules 
are rapidly degraded, the DNA back-
bone of the reprogrammed cells remains 
intact and is indistinguishable from that 
of the original wild-type cells. Finally, 
the use of iPS cells to treat heritable skin 
diseases will require transduction of the 
missing or nonfunctional gene to the 
cells (such as type VII collagen into iPS 
cells generated from patients with RDEB) 
for patients who do not display revertant 
mosaicism. Here again, the question of 
carcinogenesis, even if a hypothetical 
possibility, has been raised when ret-
roviral vectors have been used to insert 
the transgene. Along these lines, gene-
correction strategies, such as zinc-finger 
nuclease technology, have emerged as 
viable alternatives for the repair of muta-
tions in iPS cells (Urnov et al., 2010).
It is clear at this point that iPS cells 
can provide a useful model for studying 
the mechanisms of diseases, and these 
cell systems can be used for large-scale 
screens in the development of candidate 
drugs. Novel technologies relating to iPS 
cells are rapidly being developed (Csete, 
2010; Warren et al., 2010), and the three 
papers highlighted above mark a signifi-
cant milestone in skin biology because 
they demonstrate differentiation of both 
human and mouse iPS cells into kerati-
nocytes. Refinements in the generation of 
such cells may provide treatment options 
for heritable skin diseases such as RDEB 
sooner than we realize.
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Cellular heterogeneity is a frequently noted feature of melanoma. As reported in 
this issue, Kupas et al. identified heterogeneous expression of receptor activator 
of nuclear factor-κB (RANK) in melanoma cells in tumors and peripheral blood 
from patients. Increased expression of RANK was associated with the presence 
of metastatic disease and increased tumorigenicity in melanoma cells, raising the 
possibility that RANK signaling contributes to melanoma progression.
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least some melanoma cells that enter the 
circulation after dislodging from tumors 
must not only harbor intrinsic malignant 
Clinical Implications
•  Generation of iPS cells provides an essentially unlimited source of cells 
with the potential to differentiate into any cell type in the body.
•  iPS cells have been shown to differentiate into keratinocytes with the 
capacity to form skin-like structures.
•  iPS cells may provide a personalized, patient-specific approach to treat 
skin diseases such as EB.
